Welcome to our dedicated page for Vext Science news (Ticker: VEXTF), a resource for investors and traders seeking the latest updates and insights on Vext Science stock.
Vext Science Inc. reports developments for a U.S.-based cannabis operator with vertical operations in Arizona and Ohio. The company owns and operates cultivation facilities, manufacturing assets and dispensaries, and manufactures the Vapen brand of THC concentrates, edibles and distillate cartridges in Arizona.
Recurring news includes quarterly and annual financial results, operating cash flow and EBITDA updates, Ohio retail scaling, Arizona cultivation and manufacturing footprint decisions, and cannabis market activity across its core states. Company updates also cover shareholder meeting results, ownership disclosures, capital-structure matters involving multiple voting and subordinate voting shares, and trading references for its CSE-listed shares and OTCQX symbol VEXTF.
Vext Science (OTCQX:VEXTF), a U.S.-based cannabis operator active in Arizona and Ohio, entered into an investor relations agreement with Zuanic & Associates starting May 15, 2026.
Zuanic will provide advisory, research and investor relations services for up to US$7,000 per month over a twelve-month term.
Vext (OTCQX:VEXTF) will release Q1 2026 financial results before market open on May 21, 2026. Management will host a conference call and webcast at 8:00 am ET the same day for investors to review and discuss the quarter.
Vext (OTCQX: VEXTF) reported fiscal 2025 revenue of $51.4M, up 43% year-over-year, with Adjusted EBITDA of $10.9M and operating cash flow of $11.7M (up 256% YoY). Q4 revenue was $13.7M with a $5.0M non-cash goodwill/intangible impairment in Columbus.
The company expanded Ohio retail to five locations, is pursuing the state cap of eight dispensaries by early 2027, and plans to exit Eloy cultivation in Arizona to sell the facility and redeploy capital toward Ohio growth. Prior-period financials were restated for inventory amortization, prepaid asset classification, and uncertain tax positions.
Vext Science (OTCQX: VEXTF) announced a revised timing for its fourth quarter and fiscal 2025 financial results. The company now expects to release results for the period ended December 31, 2025 before market open on Wednesday, April 29, 2026.
Vext will host a conference call and webcast the same day at 8:00 am ET; replay and webcast will be available on Vext's investor website after the call.
Vext Science (OTCQX: VEXTF) will discontinue cultivation at its Eloy, Arizona facility and pursue a sale, redeploying key equipment to support an expansion at its Jackson, Ohio cultivation site.
Expected benefits include ~$2 million in avoided capex, application of net sale proceeds to reduce mortgage debt, improved Arizona adjusted EBITDA margins, and a streamlined cash conversion cycle; Eloy is to be decommissioned by end of Q2 2026. Vext will report Q4 and fiscal 2025 results on April 23, 2026.
Vext Science (OTCQX: VEXTF) received a provisional dual-use dispensary license for a Columbus, Ohio site, its seventh Ohio location. Construction is expected to begin in March 2026 with operations targeted for Q4 2026, subject to regulatory approvals. Total capital costs are estimated at $3.3 million. The move advances Vext toward Ohio's eight-store cap and leverages its Tier I cultivation and manufacturing footprint, including a 25,000 sq ft cultivation facility expandable to 50,000 sq ft.
Vext Science (OTC:VEXTF) early warning: Jason T. Nguyen sold and converted securities and updated his beneficial ownership.
On Dec 24, 2025 Mr. Nguyen entered into Share Purchase Agreements that resulted in the conversion and sale of 20,340 Multiple Voting Shares (each convertible into 100 Subordinate Voting Shares), effective Dec 31, 2025. He received US$305,100, applied as partial repayment of his promissory note to the company. His holdings changed from 493,261 MV / 1,425,300 SV to 473,291 MV / 1,425,300 SV and 100,000 options, moving MV ownership from 73.3% to 72.5% and diluted SV ownership from 20.52% to 19.7% (partially diluted basis).
Vext Science (OTCQX: VEXTF) announced final voting results from its Annual General Meeting held on December 11, 2025 in Vancouver, British Columbia.
Shareholders approved all matters in the management information circular, with each resolution passing with over 97% of votes cast, representing 74% of votes associated with issued and outstanding shares.
For additional details, investors can visit the company investor website or contact the investor relations team.
Vext Science (OTCQX: VEXTF) issued a corrected Q3 2025 results on November 20, 2025, revising EBITDA to $1.828M, Adjusted EBITDA to $1.625M and Adjusted EBITDA margin to 12.8% from previously disclosed higher amounts. Revenue for Q3 2025 was $12.7M, up 41% YoY, driven by expanded Ohio retail and steady Arizona performance. Year-to-date operating cash flow improved to $8.5M versus $(0.7)M a year earlier. The company expanded to five consolidated Ohio dispensaries and expects to reach an eight-dispensary cap in 2026. Vext refilled its MD&A to reflect the corrected metrics and scheduled a Q3 2025 earnings call on November 20, 2025.
Vext (OTCQX: VEXTF) reported Q3 2025 revenue of $12.7M, up 41% YoY, driven by expanded Ohio retail operations and steady Arizona store performance. Year-to-date operating cash flow reached $8.5M versus $(0.7)M in the prior-year period. Adjusted EBITDA for Q3 was $2.112M (16.7% margin), down from 32% a year earlier. The company reported a Q3 net loss of $2.628M and positive net cash from operations of $1.259M in the quarter. Vext now operates five consolidated Ohio dispensaries and says it is on track to reach the eight-license cap in 2026.
Management expects continued operational momentum, improved Q4 cash flow as Q3 inventory is worked through, and ongoing construction/licensing of three Ohio locations for 2026.